Company news

IDEAYA Biosciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

IDEAYA Announces IND Clearance by U.S. FDA enabling Phase 1 Initiation for First-in-Class PARG Development Candidate IDE161

January 8, 2023

IDEAYA Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023

January 2, 2023

IDEAYA Biosciences Appoints Dr. Karlene Cimprich, Ph.D. and Dr. Kornelia Polyak, M.D., Ph.D. to Scientific Advisory Board

December 18, 2022

IDEAYA Biosciences Announces Submission of IND Application to the U.S. FDA for PARG Development Candidate IDE161

December 11, 2022

IDEAYA Biosciences Receives Fast Track Designation for Darovasertib Combination Therapy with Crizotinib for the Treatment of Metastatic Uveal Melanoma

December 4, 2022

IDEAYA Biosciences Announces Agenda Topics and Key Opinion Leader Presenters for Investor R&D Day Webcast on Monday, December 12, 2022

November 28, 2022

IDEAYA Biosciences Appoints Darrin M. Beaupre, M.D., Ph.D., as Chief Medical Officer to Lead Clinical Development of Expanding Clinical Pipeline

November 27, 2022

IDEAYA Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

November 7, 2022

IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Upcoming Investor Conferences

October 31, 2022

IDEAYA Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First-Patient-In for Multiple Combination Cohorts in MTAP-Deletion Tumors

October 17, 2022

IDEAYA Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

September 18, 2022

IDEAYA Announces Pricing of Public Offering of Common Stock

September 13, 2022

IDEAYA Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma

September 10, 2022

IDEAYA Announces First-Patient-In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in (Neo)Adjuvant Uveal Melanoma

September 5, 2022

IDEAYA Biosciences to Participate in Investor Conferences in September 2022

August 29, 2022

IDEAYA Announces Achievement of First Milestone in Ongoing Collaboration with GSK for Potential First-in-Class Pol Theta Helicase Inhibitor Development Candidate

August 28, 2022

IDEAYA Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

August 14, 2022

IDEAYA Announces IDE397 Clinical Program Update and ctDNA Molecular Responses Demonstrating Tumor Pharmacodynamic Modulation

July 26, 2022

IDEAYA Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors

July 26, 2022

IDEAYA Announces Development Candidate Nomination of a Potential First-in-Class Pol Theta Helicase Inhibitor in Collaboration with GSK

June 27, 2022

IDEAYA Biosciences to Present at the 2022 Jefferies Global Healthcare Conference

June 7, 2022

IDEAYA Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

May 9, 2022

IDEAYA Biosciences to Participate in Investor Conferences in May 2022

May 2, 2022

IDEAYA Biosciences Receives Orphan Drug Designation for Darovasertib, a PKC Inhibitor, for the Treatment of Uveal Melanoma

May 1, 2022

IDEAYA Biosciences Appoints Catherine Mackey, Ph.D., to its Board of Directors

April 5, 2022

IDEAYA Biosciences Reports IDE397 Interim Phase 1 Clinical Data

March 14, 2022

IDEAYA Biosciences, Inc. Reports 2021 Financial Results and Provides Business Update

March 14, 2022

IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreements for Evaluation of Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma and Additional cMET-Driven Tumors

March 13, 2022

IDEAYA Biosciences Announces Investor Webcast to Report Interim IDE397 Phase 1 Clinical Data and Corporate Update

March 7, 2022

IDEAYA Biosciences to Participate in Investor Conferences in March 2022

February 28, 2022

IDEAYA Biosciences to Participate in Investor Conferences in February 2022

January 31, 2022

IDEAYA Advances First-in-Class PARG Development Candidate, IDE161, into IND-Enabling Studies and Exercises Option with Cancer Research UK and University of Manchester for Exclusive Worldwide License

January 30, 2022

IDEAYA Biosciences Announces Corporate and Portfolio Update for J.P. Morgan 40th Annual Healthcare Conference

January 9, 2022

IDEAYA Biosciences Announces Acquisition of Proprietary INQUIRE™ Chemical Library to Enhance Synthetic Lethality Drug Discovery Platform

January 4, 2022

IDEAYA Biosciences Appoints Dr. Frank McCormick as Chair of Scientific Advisory Board

January 3, 2022

IDEAYA Biosciences to Participate in Investor Conferences in January 2022

January 2, 2022

IDEAYA Reports Clinical Data from Phase 2 Expansion Dose of Darovasertib and Crizotinib Synthetic Lethal Combination in Heavily Pre-Treated Metastatic Uveal Melanoma

December 6, 2021

IDEAYA Biosciences to Participate in Investor Conferences in December 2021

November 29, 2021

IDEAYA Announces Investor Webcast to Review Clinical Data from Phase 1/2 Trial of Darovasertib Combination with Crizotinib in Metastatic Uveal Melanoma

November 28, 2021

IDEAYA Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

November 14, 2021

IDEAYA Biosciences to Participate in Investor Conferences in November 2021

October 31, 2021

IDEAYA Biosciences Appoints Michael White, Ph.D., as Chief Scientific Officer

October 17, 2021

IDEAYA Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update

August 9, 2021

IDEAYA Announces IDE397 Phase 1 Clinical Pharmacodynamic Data and Phase 2 Initiation of Darovasertib and Crizotinib Combination

June 27, 2021

IDEAYA Announces Dose Expansion in Phase 1/2 Study of Darovasertib and Crizotinib Combination based on Early Clinical Efficacy in First Combination Cohort

May 9, 2021

IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021

April 18, 2021

IDEAYA Reports Darovasertib (IDE196) Monotherapy Overall Survival Data and Observes Early Partial Responses in Binimetinib Combination in Metastatic Uveal Melanoma

April 15, 2021

IDEAYA Announces Investor Day Webcast to Review Clinical Data from Phase 1/2 Trial of Darovasertib (IDE196) Monotherapy and Combination with Binimetinib in Metastatic Uveal Melanoma

April 14, 2021

IDEAYA Biosciences, Inc. Reports Fourth Quarter 2020 Financial Results and Provides Business Update

March 22, 2021

IDEAYA Announces Presentations at AACR Annual Meeting 2021 for Synthetic Lethality Programs IDE397 and PARG, and Kinase Inhibitor IDE196

March 10, 2021

← Newer news releases · Older news releases →

Decks

The 5 newest of 23 decks. Every deck is listed under its year.